Read by QxMD icon Read

Papillomavirus Research

Noelia López, Ángel Gil-de-Miguel, Raquel Pascual-García, Jose Manuel Ramón Y Cajal, Ruth Gil-Prieto
BACKGROUND: Vulvar and vaginal cancers are considered rare cancers in women. Human Papillomavirus is responsible for 30%-76% of them. The aim of this study was to describe the burden of hospital admissions by malignant neoplasia (MN) and in situ carcinoma (ISC) of vulva and vagina from 2009 to 2013, in Spain METHODS: This observational, descriptive study used discharge information obtained from the national surveillance system for hospital data, Conjunto Mínimo Básico de Datos, CMBD, provided by the Ministry of Health...
February 16, 2018: Papillomavirus Research
Aaron Ermel, Marcia L Shew, Teresa M Imburgia, Matt Brown, Brahim Qadadri, Yan Tong, Darron R Brown
PURPOSE: To assess whether HPV 16 originally detected in adolescent women can be redetected in adulthood. METHODS: A convenience sample of 27 adult women with known HPV 16 detection during adolescence was assessed for HPV 16 redetection. A comparison of the long control region (LCR) DNA sequences was performed on some of the original and redetected HPV 16 isolates. RESULTS: Median age at reenrollment was 27.5 years (interquartile range of 26...
January 16, 2018: Papillomavirus Research
Anna-Lise Williamson, Suzanne Garland, Joel Palefsky, Ed Rybicki, Margaret Stanley, Silvia de Sanjosé
No abstract text is available yet for this article.
December 30, 2017: Papillomavirus Research
Aleyo Chabeda, Romana J R Yanez, Renate Lamprecht, Ann E Meyers, Edward P Rybicki, Inga I Hitzeroth
Cancer is the second leading cause of death worldwide, and it is estimated that Human papillomavirus (HPV) related cancers account for 5% of all human cancers. Current HPV vaccines are extremely effective at preventing infection and neoplastic disease; however, they are prophylactic and do not clear established infections. Therapeutic vaccines which trigger cell-mediated immune responses for the treatment of established infections and malignancies are therefore required. The E6 and E7 early genes are ideal targets for vaccine therapy due to their role in disruption of the cell cycle and their constitutive expression in premalignant and malignant tissues...
December 19, 2017: Papillomavirus Research
Ángela María Ruiz-Sternberg, Edson D Moreira, Jaime A Restrepo, Eduardo Lazcano-Ponce, Robinson Cabello, Arnaldo Silva, Rosires Andrade, Francisco Revollo, Santos Uscanga, Alejandro Victoria, Ana María Guevara, Joaquín Luna, Manuel Plata, Claudia Nossa Dominguez, Edison Fedrizzi, Eugenio Suarez, Julio C Reina, Misoo C Ellison, Erin Moeller, Michael Ritter, Christine Shields, Miguel Cashat, Gonzalo Perez, Alain Luxembourg
BACKGROUND: A 9-valent human papillomavirus (HPV6/11/16/18/31/33/45/52/58; 9vHPV) vaccine was developed to expand coverage of the previously developed quadrivalent (HPV6/11/16/18; qHPV) vaccine. METHODS: Efficacy, immunogenicity, and safety outcomes were assessed in Latin American participants enrolled in 2 international studies of the 9vHPV vaccine, including a randomized, double-blinded, controlled with qHPV vaccine, efficacy, immunogenicity, and safety study in young women aged 16-26 years, and an immunogenicity and safety study in girls and boys aged 9-15 years...
December 18, 2017: Papillomavirus Research
Eli D Ehrenpreis, Dylan G Smith
BACKGROUND: Women with cervical cancer often have anal human papillomavirus (HPV) infection and anal dysplasia. However, effectiveness of anal HPV screening is unknown. METHODS: A dynamic model was constructed using STELLA. Populations are represented as "stocks" that change according to model rates. Initial anal cytology in new cervical cancer patients, dysplasia progression and regression, cost of treating high-grade squamous intraepithelial lesions (HSIL), and lifetime costs for anal cancer care were extrapolated from the literature...
December 13, 2017: Papillomavirus Research
Philippe Gorphe, Younès Chekkoury Idrissi, Yungan Tao, Antoine Schernberg, Dan Ou, Stéphane Temam, Odile Casiraghi, Pierre Blanchard, Haïtham Mirghani
OBJECTIVES: We investigated the prognostic value of pre-treatment hematological parameters in patients with p16-positive oropharyngeal squamous-cell carcinoma (OPSCC). MATERIAL AND METHODS: Neutrophil count, lymphocyte count, neutrophil-to-lymphocyte ratio (NLR), and hemoglobin concentration measurement (Hb), were collected on day one of treatment. Endpoints were overall survival (OS) and progression-free survival (PFS). All patients were planned to receive concurrent chemoradiation...
December 11, 2017: Papillomavirus Research
Kathleen B Cartmell, Jennifer Young-Pierce, Shannon McGue, Anthony J Alberg, John S Luque, Maria Zubizarreta, Heather M Brandt
OBJECTIVE: The objective was to investigate how state level strategies in South Carolina could maximize HPV vaccine uptake. DESIGN: An environmental scan identified barriers, facilitators, and strategies for improving HPV vaccination in South Carolina. Interviews were conducted with state leaders from relevant organizations such as public health agencies, medical associations, K-12 schools, universities, insurers, and cancer advocacy organizations. A thematic content analysis design was used...
December 7, 2017: Papillomavirus Research
Ovidiu Tatar, Samara Perez, Anila Naz, Gilla K Shapiro, Zeev Rosberger
BACKGROUND: Most college males are not immunized against the human papillomavirus (HPV) and are at high risk of HPV infection. Most research of correlates of HPV vaccine acceptability in college males has assessed vaccine acceptability as a binary outcome, e.g., vaccinated or not vaccinated, without considering that some students may not even be aware that the HPV vaccine can be given to males. Our objective was to evaluate the psychosocial correlates of HPV acceptability in college males, based on multiple stages of HPV decision-making...
December 2017: Papillomavirus Research
Jenny C McCloskey, W Martin Kast, James P Flexman, Dugald McCallum, Martyn A French, Michael Phillips
BACKGROUND: Anal intraepithelial neoplasia is associated with high-risk human papillomavirus (hrHPV) as a precursor to anal cancer. However, factors other than hrHPV are likely to be involved and further study of cofactors is required because of the possibility of syndemic interactions. METHODS: Three hundred and fourteen patients underwent 457 operations. Histopathology and hrHPV testing using the Digene Hybrid Capture 2 (HC 2) method were performed. Demographic factors and sexually transmissible infections (STIs) were recorded...
December 2017: Papillomavirus Research
Karl Ulrich Petry, Clemens Liebrich, Alexander Luyten, Martina Zander, Thomas Iftner
OBJECTIVE: We examined a large series of biopsy-proven invasive cervical cancers with surgical staging and HPV re-testing to estimate the relevance of HPV-negative cervical cancers in a Caucasian population. METHODS: We prospectively collected smears from 371 patients with a biopsy-proven diagnosis of cervical cancer for HC2 testing of high-risk HPV (HR-HPV). In HC2-negative cases, smears and paraffin embedded tissue blocks underwent additional HPV genotyping. RESULTS: HC2 tests showed 31/371 cases (8...
December 2017: Papillomavirus Research
Alyssa M Cornall, Marin Poljak, Suzanne M Garland, Samuel Phillips, Dorothy A Machalek, Jeffrey H Tan, Michael A Quinn, Sepehr N Tabrizi
PURPOSE: To compare human papillomavirus genotype-specific performance of two genotyping assays, Anyplex II HPV28 (Seegene) and EuroArray HPV (EuroImmun), with Linear Array HPV (Roche). METHODS: DNA extracted from clinican-collected cervical brush specimens in PreservCyt medium (Hologic), from 403 women undergoing management for detected cytological abnormalities, was tested on the three assays. Genotype-specific agreement were assessed by Cohen's kappa statistic and Fisher's z-test of significance between proportions...
December 2017: Papillomavirus Research
Katherine E Gallagher, Natasha Howard, Severin Kabakama, Sandra Mounier-Jack, Helen E D Burchett, D Scott LaMontagne, Deborah Watson-Jones
INTRODUCTION: Since 2007, HPV vaccine has been available to low and middle income countries (LAMIC) for small-scale 'demonstration projects', or national programmes. We analysed coverage achieved in HPV vaccine demonstration projects and national programmes that had completed at least 6 months of implementation between January 2007-2016. METHODS: A mapping exercise identified 45 LAMICs with HPV vaccine delivery experience. Estimates of coverage and factors influencing coverage were obtained from 56 key informant interviews, a systematic published literature search of 5 databases that identified 61 relevant full texts and 188 solicited unpublished documents, including coverage surveys...
December 2017: Papillomavirus Research
Carine Dochez, Rosemary J Burnett, Symplice Mbola Mbassi, Fred Were, Andrew Musyoki, Daisy Trovoada, M Jeffrey Mphahlele
Several African countries have recently introduced or are currently introducing the HPV vaccine, either nationwide or through demonstration projects, while some countries are planning for introduction. A collaborative project was developed to strengthen country adolescent immunisation programmes and health systems in the African Region, addressing unique public health considerations of HPV vaccination: adolescents as the primary target group, delivery platforms (e.g. school-based and facility based), socio-behavioural issues, and the opportunity to deliver other health interventions alongside HPV vaccination...
December 2017: Papillomavirus Research
Abate Assefa Bashaw, Graham R Leggatt, Janin Chandra, Zewen K Tuong, Ian H Frazer
High-risk human papillomaviruses (HR-HPV) infect basal keratinocytes, where in some individuals they evade host immune responses and persist. Persistent HR-HPV infection of the cervix causes precancerous neoplasia that can eventuate in cervical cancer. Dendritic cells (DCs) are efficient in priming/cross-priming antigen-specific T cells and generating antiviral and antitumor cytotoxic CD8+ T cells. However, HR-HPV have adopted various immunosuppressive strategies, with modulation of DC function crucial to escape from the host adaptive immune response...
December 2017: Papillomavirus Research
Shams Rahman, Anna R Giuliano, Dana E Rollison, Michael Pawlita, Tim Waterboer, Luisa L Villa, Eduardo Lazcano Ponce
Seroepidemiology of human papillomaviruses (HPV) among men is poorly understood. We examined the association between seropositivity to cutaneous HPV and 9-valent HPV (9vHPV) types. Six hundred men were randomly selected from the HPV Infection in Men (HIM) Study. Archived serum specimens were tested for antibodies against 9vHPV types [low-risk (6/11) and high-risk (16/18/31/33/45/52/58)], and 14 cutaneous types, including β-types 5/8/12/14/17/22/23/24/38/47, α-type-27, γ-type-4, µ-type-1, and ν-type-41, using a GST L1-based multiplex serology assay...
December 2017: Papillomavirus Research
Alex Vorsters, Marc Arbyn, Marc Baay, Xavier Bosch, Silvia de Sanjosé, Sharon Hanley, Emilie Karafillakis, Pier Luigi Lopalco, Kevin G Pollock, Joanne Yarwood, Pierre Van Damme
The Human Papillomavirus Prevention and Control Board brought together experts to discuss optimizing HPV vaccination and screening programs. Board members reviewed the safety profile of licensed HPV vaccines based on clinical and post-marketing data, reaching a consensus that current safety data is reassuring. Successful vaccination programs used well-coordinated communication campaigns, integrating (social) media to spread awareness. Communication of evidence supporting vaccine effectiveness had beneficial effects on the perception of the vaccine...
December 2017: Papillomavirus Research
A P Ortiz, V Tamayo, A Scorsone, M Soto-Salgado, I Febo, P Piovanetti, H L Venegas-Ríos, Y Yamamura, C Zorrilla
OBJECTIVES: Puerto Rico (PR), is the fifth highest jurisdiction of the United States of America (US) with respect to HIV prevalence and the leading in cervical cancer incidence. This cross-sectional study describes the prevalence and correlates of cervical HPV infection among a clinic-based sample of 302 women living with HIV/AIDS in PR. METHODS: Data collection included questionnaires, blood and cervical samples. Multivariable logistic regression models were used to estimate the magnitude of association (adjusted Prevalence odds ratio [aPOR]) between HPV cervical infection and other covariates...
December 2017: Papillomavirus Research
S M Garland, J M L Brotherton, A B Moscicki, A M Kaufmann, M Stanley, N Bhatla, R Sankaranarayanan, S de Sanjosé, J M Palefsky
It is well-established that immunocompromised people are at increased risk of HPV-related disease compared with those who are immunocompetent. Prophylactic HPV sub-unit vaccines are safe and immunogenic in immunocompromised people and it is strongly recommended that vaccination occur according to national guidelines. When delivered to immunocompromised populations, HPV vaccines should be given as a 3-dose regimen.
December 2017: Papillomavirus Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"